Alexion Pharma (ALXN) Tops Q4 EPS by 1c; Guides Below the Street, $1B Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Lowered to $158 at BMO Capital Citing Competition for PNH
February 17, 2017 6:54 AM ESTBMO Capital Markets analyst M. Ian Somaiya reiterates Outperform rating, lowers price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158 (from $166), suggesting the market has missed the impact of competition on the companys PNH franchise, despite managements positive 2017 outlook for Solaris.
Somaiya... More
Alexion Pharma (ALXN) Plans to Be 'Very Active' on Deal Opportunities
February 16, 2017 11:11 AM ESTOn its call, Alexion Pharma (NASDAQ: ALXN) said it will be very active in deal makings
".. very active from a Business Development perspective to identify opportunities that we think fit with our model and with our strategy and bring them in... More
Alexion Pharma (ALXN) interim CEO says prior guidance for 2018 cannot be relied on
February 16, 2017 10:51 AM ESTOn call, Alexion Pharma (NASDAQ: ALXN) interim CEO says prior guidance for 2018 cannot be relied on but too early for new projections.
... More